Dr. Daniela Pankova

Dr. Daniela Pankova established Terasom Ltd. In 2019 and currently serves as President and Chief Executive Officer for the company. She has spent 15 years in cancer research field, focused on tumor microenvironment and metastatic spreading. After receiving her doctoral degree at Charles Univerity, she served as a postdoctoral fellow at MD Anderson Cancer Center in Houston, TX, USA and at Oxford University in England. Dr. Pankova was involved in numerous research interdisciplinary projects and has been extensively published in the cancer research field.

Jonathan Adrian Jackson

A few years after completing his degree in Business Management in London, Jonathan Jackson set up his own company to develop commercial real estate in Central Europe. Over the last 25 years, he has currently under development and developed more than 15,000,000 sqft of space. Since selling a portfolio of completed assets in early 2007 in one of the largest deals in Central Europe and Africa, Mr Jackson has diversified and invested over $15M in different business sectors, in the USA, Europe and Africa with great success.

Jonathan Meigs Kurie, MD

Professor Jonathan Kurie holds an MD degree from Chapel Hill Medical school in North Carolina and has more than 40 years of experience in lung oncology and lung cancer research at MD Anderson Cancer center, Houston, USA. In the past, Professor Jonathan Kurie led a few clinical trials at MD Anderson Cancer Center, focused on the effects of dietary supplements on lung cancer development. Besides of his very successful clinical career and cancer research publication activity in high impact factor international journals, Professor Kurie is successfully awarded by various prestigious grants over his entire clinical and scientific career.

Mr. Nicholas Adams

Mr. Nicholas Adams holds law degree from College of Law in London and over the past 35 years he has been working as chief business officer at various anti-cancer drug development companies, including company focused on application of exosomes in neurodegenerative diseases. Mr. Adams was involved in many successful deals from which the most outstanding was to out-license the product for $161M.